Cancer
Intraductal Papillary Neoplasm of the Bile Duct
CI-CAN-00009369Explore in graph →
208 active trials3 approved drugs29 evidence items
- OncoTree
- IPN
Loading cancer entity…
Cancer
CI-CAN-00009369Explore in graph →
Clinical trials
758 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (106)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06440018 | INSPIRE: a Multi-Cancer Early Detection Study(INSPIRE) | unknown | — | 5,350 | Singlera Genomics Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT06763250 | In This Study, a Retrospective Analysis Was Conducted to Explore the Risk Factors for Patients Undergoing Pancreaticoduodenal Surgery (PD) to Achieve TO, and a Nomogram Prediction Model Was Further Established to Promote the Standardization and Standardization of PD Surgical Quality Evaluation. | unknown | — | 280 | luokai zhang |
| 1 |
| Jan 8, 2025 |
| clinicaltrials |
| NCT05215665 | GEMOX Combined With Targeted Therapy and Immunotherapy for Patients With Advanced Cholangiocarcinoma | unknown | N/A | 146 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | unknown | Phase 1 / Phase 2 | 179 | NGM Biopharmaceuticals, IncINDUSTRY | 3 | Oct 2, 2024 | clinicaltrials |
| NCT06505486 | GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC | unknown | — | 21 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 17, 2024 | clinicaltrials |
| NCT06417606 | Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 20 | Zhiyong HuangOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06375642 | A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC | unknown | Phase 2 | 30 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT06369480 | Prognostic Factors for Survival in Patients With Cholangiocarcinoma | unknown | — | 2,000 | Rigshospitalet, DenmarkOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06363123 | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis | unknown | — | 2,700 | Beijing Friendship HospitalOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT05519605 | Bile Duct Drainage After ERCP Failure: EUS-BD vs PTBD(BESTDRAIN) | unknown | — | 61 | Radboud University Medical CenterOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT06335927 | HAIC Combined With Cadonilimab and Regorafenib as 2nd-line Treatment for ICC | unknown | Phase 2 | 45 | Fudan UniversityOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06304766 | Open Versus Laparoscopic Ablation of Liver Malignancies(OPTIMAL) | unknown | N/A | 80 | Rigshospitalet, DenmarkOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT05872867 | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90) | unknown | Phase 1 | 54 | Wellmarker BioINDUSTRY | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05124002 | Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma | unknown | Phase 4 | 66 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03924466 | Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients(VUBAR) | unknown | Phase 2 | 55 | Universitair Ziekenhuis BrusselOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT04149691 | Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies | unknown | Phase 1 | 42 | Celon Pharma SAINDUSTRY | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06192784 | Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma(CCGLC-012) | unknown | Phase 2 | 36 | Tongji HospitalOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT06194695 | DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma(CCGLC-009) | unknown | — | 100 | Ze-yang Ding, MDOTHER | 1 | Jan 9, 2024 | clinicaltrials |
| NCT02611453 | Cholangiography Using Carbon Dioxide Versus Iodinated Contrast in ERCP | unknown | N/A | 40 | University of VirginiaOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT05600803 | Screening Single-operator Cholangioscopy for Neoplastic Bile Duct Lesions | unknown | — | 236 | Soonchunhyang University HospitalOTHER | 1 | Nov 27, 2023 | clinicaltrials |
| NCT06134193 | Combination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer | unknown | Phase 2 | 41 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 0 | Nov 18, 2023 | clinicaltrials |
| NCT05781958 | Cadonilimab Combined With Gem/Cis as First Line Therapy in Patients With Advanced ICC | unknown | Phase 2 | 64 | Shen FengOTHER | 1 | Nov 2, 2023 | clinicaltrials |
| NCT06106750 | Endoscopic Scissors Cutting Nasobiliary Duct VS Bilateral Plastic Stent | unknown | N/A | 122 | First People's Hospital of HangzhouOTHER | 1 | Oct 30, 2023 | clinicaltrials |
| NCT06081322 | A Study to Evaluate the Safety and Efficacy of PRRT With 177Lu-EB-FAPI in Patients With Advanced Cholopancreatic Tumors(CISPD-5) | unknown | Phase 1 | 29 | Zhejiang UniversityOTHER | 1 | Oct 13, 2023 | clinicaltrials |
| NCT06048289 | Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy | unknown | — | 150 | Zhejiang Cancer HospitalOTHER | 1 | Sep 25, 2023 | clinicaltrials |
| NCT05681949 | Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards(ADBoard) | unknown | N/A | 1,200 | Charite University, Berlin, GermanyOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05233293 | Spyglass+RFA Versus Cytobrush+RFA for Extrahepatic Cholangiocarcinoma | unknown | N/A | 200 | First People's Hospital of HangzhouOTHER | 1 | Aug 15, 2023 | clinicaltrials |
| NCT05957250 | [68Ga]Ga-FAPI-46 Positron Emission Tomography (PET) Scan to Improve the Imaging of Pancreatic and Bile Duct Cancer(PANSCAN-1) | unknown | N/A | 63 | Amsterdam UMC, location VUmcOTHER | 1 | Jul 24, 2023 | clinicaltrials |
| NCT05595122 | EUS-guided Choledochoduodenostomy for Primary Drainage of Malignant Distal Biliary Obstruction(SCORPION-II-p) | unknown | N/A | 25 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jul 20, 2023 | clinicaltrials |
| NCT04445532 | Hepatobiliary Tumors Tissue Samples Acquisition | unknown | — | 450 | Peking Union Medical College HospitalOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05913661 | Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT03820310 | Clinical Trial of Autologous Tcm Immunotherapy in ICC | unknown | Phase 2 | 20 | Newish Technology (Beijing) Co., Ltd.INDUSTRY | 1 | May 24, 2023 | clinicaltrials |
| NCT04454905 | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study | unknown | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | Apr 19, 2023 | clinicaltrials |
| NCT05400902 | HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 17 | Binkui LiOTHER | 1 | Apr 13, 2023 | clinicaltrials |
| NCT05805956 | IMM2902 in Patients With Advanced Solid Tumors Expressing HER2 | unknown | Phase 1 / Phase 2 | 105 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Apr 10, 2023 | clinicaltrials |
| NCT04565275 | A Study of ICP-192 in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 45 | Beijing InnoCare Pharma Tech Co., Ltd.INDUSTRY | 2 | Mar 14, 2023 | clinicaltrials |
| NCT05374122 | AI Guidance for Biopsy in Suspected Cholangiocarcinoma | unknown | N/A | 48 | Instituto Ecuatoriano de Enfermedades DigestivasOTHER | 1 | Mar 6, 2023 | clinicaltrials |
| NCT05694845 | Evaluation of the Patient's Experience in Medical Studies for Cholangiocarcinoma | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | Mar 6, 2023 | clinicaltrials |
| NCT05519319 | Safety and Efficacy of PDT vs RFA vs PDT+RFA for the Treatment of Extrahepatic Cholangiocarcinoma | unknown | N/A | 70 | First People's Hospital of HangzhouOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05721963 | Study on the Accuracy of Proteomics in Evaluating Lymph Node Metastasis Status in Cholangiocarcinoma Patients | unknown | — | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 10, 2023 | clinicaltrials |
| NCT05718349 | FGF19 in Obstructive Cholestasis: "Unveil the Signal"(FOCUS) | unknown | — | 81 | Nicole HildebrandOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT05697237 | Carlizumab Plus Sovantinib in Second-line Treatment of Advanced or Metastatic Cholangiocarcinoma | unknown | N/A | 60 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Jan 25, 2023 | clinicaltrials |
| NCT05672537 | Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk | unknown | Phase 2 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jan 5, 2023 | clinicaltrials |
| NCT05653817 | Advanced or Metastatic Cholangiocarcinoma | unknown | N/A | 60 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 0 | Dec 16, 2022 | clinicaltrials |
| NCT05641233 | Preoperative Radiotherapy in Patients at High Risk of Postoperative Pancreatic Fistula After Pancreatoduodenectomy(FIBROPANC-1) | unknown | Phase 1 / Phase 2 | 33 | Erasmus Medical CenterOTHER | 1 | Dec 7, 2022 | clinicaltrials |
| NCT05634694 | Study on Consistency Evaluation for Drug Sensitivity of Patient-Derived Organoid Model From Cholangiocarcinoma Patients | unknown | — | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT05626127 | MRI-based Clinico-radiomics Predicting Lymph Node Metastasis Status of Hilar Cholangiocarcinoma | unknown | — | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT05580328 | An Exploratory Clinical Study of Photodynamic Therapy Combined With Sonodynamic Therapy in Cholangiocarcinoma | unknown | N/A | 10 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 0 | Nov 14, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Feb 21, 2025source: clinicaltrials